On August 2, 2023, CG Oncology, Inc., an oncolytic immunotherapy company focused on developing bladder-saving therapeutics for patients with urologic cancer, announced the close of an oversubscribed $105 million crossover financing round, co-led by new investors Foresite Capital and TCGX, with participation from Avidity Partners, BVF Partners, and Janus Henderson Investors, as well as existing investors including Acorn Bioventures, Ally Bridge Group, Decheng Capital, Longitude Capital, Malin Corporation, and RA Capital Management. Wilson Sonsini Goodrich & Rosati advised Foresite Capital on IP matters related to the transaction.

The proceeds will support the continued advancement of clinical programs in bladder cancer towards FDA approval including BOND-003, a fully enrolled, single-arm, Phase 3, monotherapy study for cretostimogene grenadenorepvec as a potential treatment for high-risk non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).

The Wilson Sonsini patent team that advised Foresite Capital was led by Laurie McNamara and included Yingchun Ni, Matthew Garnica, Sara Butterfield, , Srividya Chandramouli, and Mike Hostetler.

For more information, please see CG Oncology’s press release.